221 related articles for article (PubMed ID: 16105559)
21. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers.
Gales AC; Sader HS; Fritsche TR
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):421-7. PubMed ID: 18068934
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).
Bouchillon SK; Iredell JR; Barkham T; Lee K; Dowzicky MJ
Int J Antimicrob Agents; 2009 Feb; 33(2):130-6. PubMed ID: 18995992
[TBL] [Abstract][Full Text] [Related]
23. Tigecycline: a new glycylcycline for treatment of serious infections.
Noskin GA
Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers.
Sotto A; Bouziges N; Jourdan N; Richard JL; Lavigne JP
Pathol Biol (Paris); 2007 Nov; 55(8-9):398-406. PubMed ID: 17905534
[TBL] [Abstract][Full Text] [Related]
25. A review of tigecycline--the first glycylcycline.
Peterson LR
Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522
[TBL] [Abstract][Full Text] [Related]
26. Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Denys GA; Koch KM; Dowzicky MJ
Am J Infect Control; 2007 Oct; 35(8):521-6. PubMed ID: 17936143
[TBL] [Abstract][Full Text] [Related]
27. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria.
Iredell J; Thomas L; Power D; Mendes E
J Antimicrob Chemother; 2007 Apr; 59(4):816-8. PubMed ID: 17353224
[No Abstract] [Full Text] [Related]
28. The emergence of clinical resistance to tigecycline.
Sun Y; Cai Y; Liu X; Bai N; Liang B; Wang R
Int J Antimicrob Agents; 2013 Feb; 41(2):110-6. PubMed ID: 23127485
[TBL] [Abstract][Full Text] [Related]
29. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
30. Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
Bolmström A; Karlsson A; Engelhardt A; Ho P; Petersen PJ; Bradford PA; Jones CH
J Clin Microbiol; 2007 Aug; 45(8):2474-9. PubMed ID: 17522277
[TBL] [Abstract][Full Text] [Related]
31. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis.
Petersen PJ; Labthavikul P; Jones CH; Bradford PA
J Antimicrob Chemother; 2006 Mar; 57(3):573-6. PubMed ID: 16431863
[TBL] [Abstract][Full Text] [Related]
32. Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2006 Oct; 50(10):3507-13. PubMed ID: 16940056
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of tigecycline activity in clinical isolates among Indian medical centers.
Manoharan A; Chatterjee S; Madhan S; Mathai D
Indian J Pathol Microbiol; 2010; 53(4):734-7. PubMed ID: 21045403
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro evaluation of activity of tigecycline against susceptible and multidrug resistant organisms.
Gupta V; Bansal N; Chander J
Indian J Med Microbiol; 2012; 30(4):483-5. PubMed ID: 23183481
[No Abstract] [Full Text] [Related]
35. Influence of polysorbate-80 when determining the tigecycline MIC by the reference method.
Jones RN; Knapp CC; Dowzicky MJ
Diagn Microbiol Infect Dis; 2007 May; 58(1):145-6. PubMed ID: 17368804
[No Abstract] [Full Text] [Related]
36. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
[TBL] [Abstract][Full Text] [Related]
37. Tigecycline: a review of properties, applications, and analytical methods.
da Silva LM; Nunes Salgado HR
Ther Drug Monit; 2010 Jun; 32(3):282-8. PubMed ID: 20431506
[TBL] [Abstract][Full Text] [Related]
38. Tigecycline: in-vitro performance as a predictor of clinical efficacy.
Hawkey P; Finch R
Clin Microbiol Infect; 2007 Apr; 13(4):354-62. PubMed ID: 17359318
[TBL] [Abstract][Full Text] [Related]
39. Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
Arya SC; Agarwal N
Saudi Med J; 2008 Nov; 29(11):1558-60. PubMed ID: 18998000
[TBL] [Abstract][Full Text] [Related]
40. Establishing the role of tigecycline in an era of antimicrobial resistance.
Schafer JJ; Goff DA
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
